Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

153
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
153
Acute Pancreatitis I: Introduction01:27

Acute Pancreatitis I: Introduction

417
Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
417
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

218
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
218
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

116
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
116

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LOCAL RECURRENCE AFTER COLORECTAL ENDOSCOPIC SUBMUCOSAL DISSECTION: A LARGE INTERNATIONAL WESTERN MULTICENTER STUDY.

Gastrointestinal endoscopy·2026
Same author

Outcomes of Endoscopic Single-Gated Compared to Multigated Approach using Lumen Apposing Metal Stents in the Management of Necrotizing Pancreatitis.

Endoscopy international open·2026
Same author

A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity.

Cureus·2026
Same author

Progressive Pulmonary Lesions and Cervical Lymphadenopathy Revealing Large B-cell Lymphoma: A Rare Case Report.

Cureus·2026
Same author

Reframing Safety: Human Factors for Safer, Smarter, Human-Centered Health Care.

Journal of patient safety·2026
Same author

Concurrent Papillary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma Presenting With Hoarseness and Dysphagia.

Cureus·2026

Related Experiment Video

Updated: Jul 26, 2025

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.0K

Metformin-Induced Acute Hepatitis.

Arooj Mian1, Baha Aldeen Bani Fawwaz1, Gurdeep Singh1

  • 1Internal Medicine, AdventHealth Orlando, Orlando, USA.

Cureus
|June 13, 2023
PubMed
Summary

Metformin is a common type 2 diabetes treatment, but rare cases of liver damage can occur. This report highlights a unique instance of dose-dependent metformin-induced hepatotoxicity, urging clinical awareness of this adverse reaction.

Keywords:
diabetesdrug-induced liver injury (dili)hepatitishepatotoxicityidiosyncratic liver injuryliver diseasemetformin-induced acute hepatitismetformin-induced hepatotoxicitymetformin-induced lactic acidosiss: hepatotoxicity

More Related Videos

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.5K
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.3K

Related Experiment Videos

Last Updated: Jul 26, 2025

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.0K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.5K
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.3K

Area of Science:

  • Endocrinology
  • Hepatology
  • Pharmacology

Background:

  • Metformin is a first-line oral medication for managing hyperglycemia in type 2 diabetes mellitus (T2DM).
  • Despite its general safety profile, the increasing prevalence of T2DM necessitates awareness of rare adverse effects.
  • Hepatotoxicity is an infrequent but serious potential side effect of metformin therapy.

Observation:

  • A rare case of metformin-induced hepatotoxicity is presented.
  • This case appears to be the first reported instance of dose-dependent metformin-induced liver injury.
  • The patient's liver function normalized upon discontinuation of metformin.

Findings:

  • Metformin, a widely used T2DM drug, can rarely cause liver damage.
  • The observed hepatotoxicity demonstrated a dose-dependent relationship.
  • This suggests that higher metformin doses may increase the risk of liver injury.

Implications:

  • Clinicians should consider metformin-induced hepatotoxicity in patients with unexplained liver enzyme elevations.
  • Awareness of this rare, dose-dependent adverse effect is crucial for safe metformin prescribing.
  • Further investigation into the mechanisms of metformin hepatotoxicity may be warranted.